Rubius Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Rubius Therapeutics

04/11/2022 22:42

* Rubius Therapeutics Inc  RUBY.OQ   RUBY.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Rubius Therapeutics
Inc
is for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $10.5​, above​ its last closing price
of $0.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.54       -0.53      -0.49     Beat    7.9
 Mar. 31 2022  -0.58       -0.58      -0.58     Met     0.3
 Dec. 31 2021  -0.60       -0.59      -0.61     Missed  -3​
 Sep. 30 2021  -0.57       -0.57      -0.55     Beat    3.2
 ​​Jun.        -0.50       -0.49      -0.56     Missed  -14.7
 30 2021                                                
 Mar. 31 2021  -0.53       -0.52      -0.51     Beat    1.3​
 Dec. 31 2020  -0.52       -0.49      -0.50     Missed  -1
 Sep. 30 2020  -0.49       -0.49      -0.51     Missed  -3.4
 This summary was machine generated November 4 at 22:42 GMT.  All
figures in US dollars  unless otherwise stated